表紙
市場調查報告書

中國生物製藥合同製造市場

Growth of Biopharmaceutical Contract Manufacturing Organizations in China: An In-depth Study of Emerging Opportunities

出版商 BioPlan Associates, Inc. 商品編碼 950504
出版日期 內容資訊 英文 144 Pages
商品交期: 最快1-2個工作天內
價格
中國生物製藥合同製造市場 Growth of Biopharmaceutical Contract Manufacturing Organizations in China: An In-depth Study of Emerging Opportunities
出版日期: 2020年06月30日內容資訊: 英文 144 Pages
簡介

本報告是對中國生物製藥合同製造組織(CMO)和開發與製造合同製造組織(CDMO)市場的調查,包括生產能力,性能,產品,規模,管理,主要業務領域,產品,研發,業務和合作夥伴關係策略,優缺點和未來目標。

突出顯示

  • 中國排名最高的CMO/CDMO機構
  • 在中國承包生物製劑生產業務的重要性
  • 滿足不斷增長的需求並擴大產能
  • 中國CMO分析與概況

主要發現

    到2030年,隨著CMO擴大其國內生產份額,中國的單克隆抗體(mAb)治療市場預計將增長到260億美元。
  • 中國的管道開發以及mAb治療和疫苗市場都在加速發展。
  • 中國製造商對生物製劑的需求正以每年20%的速度增長。

此報告提供的數據:

  • 涵蓋超過75個中國合同製造組織和新設施

涵蓋75個CMO/CDMO,包括行業領導者:

  • 3S Guojian
  • Asymchem
  • AutekBio
  • Boehringer-Ingelheim
  • Shanghai
  • Canton Bio
  • CC Pharming
  • Celgen Pharma
  • Celltrion
  • Chempartner
  • C-Mab
  • Genescript
  • HJB (Transcenta)
  • Jiangsu T-Mab
  • JOINN Biologics
  • Lonza
  • Mabplex

內容

  • 第1章:簡介
  • 第2章: MAH法律框架,政府補助計劃及其影響
  • 第3章:中國生物製藥創新與商業規模生物工藝外包
  • 第4章:中國生物製劑的CMO使用情況
  • 第5章: Chinese Biologics CMO
  • 第6章:中外生物製品CDMO比較
  • 附錄:生物製藥CDMO,生物製藥和CMO公司以及開發公司
目錄
Product Code: ISBN: 978-1-934106-39-6

NEW! Comprehensive In-depth Study provides detailed analysis of the CMO indus-try, its recent development and trends.

Profiles of China's Contract Manufacturing Organizations (CMOs) and Contract Development Manufacturing Organizations (CDMOs), including their capacity, history, products, scale, management, business focus, products, R&D, business and partnering strategies, strengths and weaknesses, and future objectives.

HIGHLIGHTS

  • Top Ranked CMO/CDMO Facilities in China
  • Trends in the importance of Contract Manufacturing of biologics in China
  • How CMOs are meeting the increased demand and rapid capacity expansions
  • Analysis and Profile Directory of CMOs in China Much more...

WHY THIS REPORT:

This study will assist Western CMOs, and biopharma developers to make strategic decisions on why and when they should enter China market.

  • Identify potential clients and partners in China for Western CMOs
  • Analysis for Western mAb developers in partnering with China-based biologics CMO

TOPLINE FINDINGS

  • China mAb Therapeutics expected to grow to USD $26 billion by 2030, CMOs accessing an increasing share of domestic production.
  • Pipeline Growth in China is accelerating, as are markets for mAb therapeutics and vaccines
  • Demand for biologics from domestic developers is increasing at 20% annually

BY THE NUMBERS:

  • Over 75+ Chinese-owned Contract Manufacturing Organizations, plus up-and-coming facilities!
  • 140+ pages
  • Over 30+ Figures and 20 Tables

Coverage 75 CMO/CDMOs incluidng Industry Leaders:

  • 3S Guojian
  • Asymchem
  • AutekBio
  • Boehringer-Ingelheim
  • Shanghai
  • Canton Bio
  • CC Pharming
  • Celgen Pharma
  • Celltrion
  • Chempartner
  • C-Mab
  • Genescript
  • HJB (Transcenta)
  • Jiangsu T-Mab
  • JOINN Biologics
  • Lonza
  • Mabplex, and more

Table of Contents

  • Chapter 1: Introduction: Brief History of China Biopharma Service Industry
  • Chapter 2: Legal Framework of MAH, Government Subsidy Program and Implications
  • Chapter 3: Innovation in China Biopharma and the Outsourcing of Commercial Scale Bioprocessing
  • Chapter 4: Using China-based Biologics CMOs
  • Chapter 5: China-based Biologics CMOs
  • Chapter 6: Domestic vs. Multinational Biologics CDMOs
  • Appendix: Featuring Biopharmaceutical CDMOs, Companies with Biologics and CMO Operations and Developer companies